Zeltia and PharmaMar

Zeltia to Raise New Funds Through Institutional Placing

Madrid, Spain (ots/PRNewswire) - Zeltia S.A, the Spanish consumer chemicals and biotechnology group announces today that its Board of Directors has authorized a capital increase through a private placement with qualified international institutional investors. The capital increase is expected to raise approximately one hundred (100) million euros. A "green shoe" of up to 15% of the amount raised can be exercised by HSBC, which is the Sole Bookrunner on the transaction. The funds raised will be used to further the continued research, development and commercialisation of cancer products being developed by PharmaMar, Zeltia's biotech subsidiary. The capital increase will be made through an Accelerated Bookbuilt Offering (ABO) to qualified institutional investors and will close on Wednesday 22 June, when the price will be fixed and the shares allocated. Enquiries Isabel Lozano CEO PharmaMar S.A. C/ Reyes, 1.Colmenar Viejo Madrid 28770 Tel: +34-91-846-60-00 Catherine Moukheibir Head of Capital Market Strategy Zeltia, S.A. José Abascal , 2 Madrid 28003 Tel: +34-91-444-45-00 Coro Egaña Corporate Communications Director Zeltia , S.A. José Abascal ,2 Madrid 28003 Tel: +34-91-444-45-00 This announcement does not, and shall not, in any circumstances constitute a public offering nor an invitation to the public in connection with any offering. This announcement does not constitute or form part of any offer or solicitation to purchase or subscribe for securities in the United States or by U.S. Persons (as defined in Regulation S under the United States Securities Act of 1933, as amended (the "Securities Act")). The securities mentioned herein have not been, and will not be, registered under the Securities Act. They may not be offered or sold in the United States or to, or for the account or benefit of U.S. persons, except pursuant to an exemption from the registration requirements of the Securities Act. No public offer of the securities is being made in the United States. In the United Kingdom, this announcement is for distribution only to investment professionals, high net worth companies, partnerships, associations or trusts and investment personnel of any of the foregoing (each within the Financial Services and Markets Act 2000 (financial promotion) Order 2001) and any other persons to whom it may be communicated lawfully. The securities specified in this announcement may be subscribed exclusively by such persons. No other person should act or rely on it. Persons distributing this press release must satisfy themselves that it is lawful to do so. A folleto informativo has been registered with Spain's Comision Nacional del Mercado de Valores and offers of the securities mentioned herein can be made in Spain in accordance with applicable Spanish law and regulations and the terms of the folleto informativo. The distribution of this announcement in certain countries may constitute a breach of applicable law. About Pharmamar PharmaMar is a biopharmaceutical company pioneer in the discovery and development of novel anticancer drugs derived from marine organisms. PharmaMar's clinical portfolio currently includes five compounds: Yondelis in Phase II/III trials for solid tumours (co-developed with Johnson & Johnson Pharmaceutical Research & development), designated Orphan Drug for STS and Ovarian cancer by the European Commission (EC) and the FDA. Yondelis is being developed as a single agent and in combination therapy. Aplidin in Phase II for solid and haematological tumours, designated Orphan Drug for acute lymphoblastic leukaemia and for multiple Myeloma by the FDA and the CE. Kahalalide F in Phase II for solid tumours and severe psoriasis. ES-285 and Zalypsis in Phase I trials for solid tumours. About Zeltia Zeltia S.A. is the pioneer biotechnology company in Spain with a market capitalization of around 1.2 billion euros. The group is comprised of the following subsidiaries: PharmaMar, founded in 1986, a biopharmaceutical company devoted to the discovery and development of novel anticancer drugs derived from marine organisms. Neuropharma devoted to the discovery and development of novel drugs against Alzheimer's and other degenerative diseases of the central nervous system; Genomica which produces and sells DNA diagnostic tools; and Zelnova and Xylazel, two very profitable companies that build on Zeltia's heritage in the chemical business. ots Originaltext: Zeltia Group and PharmaMar Im Internet recherchierbar: http://www.presseportal.ch Contact: Isabel Lozano, CEO, PharmaMar S.A., Tel: +34-91-846-60-00; Catherine Moukheibir, Head of Capital Market Strategy, Zeltia , S.A., Tel: +34-91-444-45-00; Coro Egaña, Corporate Communications Director, Zeltia , S.A., Tel: +34-91-444-45-00

Das könnte Sie auch interessieren: